Matthew Kapusta

Matthew Kapusta has served 25 years in the life sciences industry and is currently Chief Executive Officer and Director of uniQure (Nasdaq: QURE), a pioneer in the field of gene therapy where he led the successful development of the world’s first approved gene therapy for people living with hemophilia B. Prior to joining uniQure, Mr. Kapusta was Senior Vice President at AngioDynamics (Nasdaq: ANGO), responsible for corporate development, strategic planning, and national sales accounts. Prior to AngioDynamics, he served as Vice President, Finance and Strategic Planning and Analysis for Smith & Nephew (NYSE: SNN). Mr. Kapusta’s career also includes more than a decade of investment banking experience where he focused on mergers, acquisitions and corporate finance transactions for emerging life sciences companies. Mr. Kapusta was Managing Director, Healthcare Investment Banking at Collins Stewart, and held various positions at Wells Fargo Securities, Robertson Stephens, and PaineWebber. Mr. Kapusta holds a Master of Business Administration from New York University’s Stern School of Business, a Bachelor of Business Administration from University of Michigan’s Ross School of Business and earned his Certified Public Accountant license in 1996 while at Ernst & Young.